Loading clinical trials...

A Phase I Study of HW201877 in Healthy Subjects | Clinical Trials | Clareo Health

RECRUITINGPHASE1

A Phase I Study of HW201877 in Healthy Subjects

A Single-Center, Randomized, Double-blind, Placebo-controlled, Single and Multiple Dosing, Dose-escalation, Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, PK/PD, Food Effect of HW201877 in Healthy Volunteers.

NCT07373457•Wuhan Humanwell Innovative Drug Research and Development Center Limited Company

View on ClinicalTrials.gov

Summary

This is a Phase I, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and food effect (FE) of HW201877 in healthy subjects following (1) a single ascending dose (Part 1), which includes a single-dose, two-period crossover FE cohort; (2) a multiple ascending dose (Part 2).

Eligibility

Age

18 - 55 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Before enrollment in the study, each subject shall sign the informed consent form and be fully apprised of the study content, implementation procedures and potential adverse reactions.
•Subjects are willing to voluntarily use effectivecontraceptives from screening to at least 6 months after the last dose administration.
•18 years to 55 years (inclusive), male and female.
•Male subjects weight ≥50 kg and female subjects weight ≥45 kg. Bodymass index (BMI) : 18-28 kg/m2 (inclusive) .

Exclusion Criteria

•Smoking more than 5 cigarettes per day within 3 months prior to screening.
•Allergic diathesis (with a history of allergies to multiple drugs and foods).
•A history of drug abuse and/or alcoholism (consuming 14 units of alcohol per week; 1 unit = 285 mL of beer, 25 mL of distilled spirits, or 100 mL of wine).
•Have taken any medications that alter hepatic enzyme activity within 28 days prior to screening.
•Have consumed special diets (including pitaya, mango, lime, grapefruit, carambola, orange, grapefruit or grapefruit-containing products, etc.) or engaged in strenuous exercise within 2 weeks prior to screening, or having other factors that may affect the absorption, distribution, metabolism and excretion of the study drug.
•Have taken any investigational drugs or participated in any other clinical drug trials within 3 months prior to the first administration of the study drug.
•Clinically significant abnormalities in clinical laboratory tests, or a history of clinically significant findings of the following diseases within 12 months prior to screening (including but not limited to gastrointestinal, renal, hepatic, neurological, hematological, endocrine, oncological, pulmonary, immunological, psychiatric, or cardio-cerebrovascular diseases).
•Unable to tolerate venipuncture, or with a history of needle phobia or hematophobia.
•Not suitable for this study as judged by the investigator.

Locations (1)

The First Hospital of Jilin University

Changchun, China

Key Dates

Start Date

June 26, 2025

Primary Completion Date

March 1, 2026

Completion Date

March 1, 2026

Last Updated

January 28, 2026

Enrollment

104

ESTIMATED participants

Conditions

Healthy ParticipantsIBD (Inflammatory Bowel Disease)

Interventions

HW201877 capsules

DRUG

Placebo

DRUG

A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity

NCT07310901

Obese But Otherwise Healthy Participants

View study

RECRUITINGPHASE1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases

NCT06342713

Healthy ParticipantsHealthy Subjects+5 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 28, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Phase I Study of HW201877 in Healthy Subjects

Inclusion Criteria

Exclusion Criteria

A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases

Study of BW-50218 in Healthy Participants

A Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SYH2085

A Phase I/II, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a Broadly Protective Sarbecovirus Vaccine (GBP511) in Healthy Adults.

ALPCO/Calprotectin CLIA Assay: Expected Values of Calprotectin in Healthy Subjects